ÐÓ°ÉÔ­´´

LabGenius has significant potential due to its innovative approach combining biopharmaceutical development with advanced machine learning. Located in London and targeting a B2B market, the company uses cutting-edge technology to accelerate the development of protein therapeutics. Traditional protein engineering methods are slow and expensive, leading to higher costs and less effective drugs. By using a machine learning-driven evolution engine, LabGenius can expedite therapeutic development, offering a faster and more cost-effective solution. With backing from Kindred Capital and Atomico, LabGenius is poised to disrupt conventional drug development and establish itself as a market leader.